ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Racial and ethnic differences in plasma p-tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemab.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Plasma Phosphorylated Tau 217 and Incident Mild Cognitive Impairment and Dementia in Older Women.JAMA network open · 2026Trial
- More efficient screening for preclinical Alzheimer's clinical trials using mixture of experts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Optimized plasma p-tau217 and p-tau217/Aβ42 cutoffs enhance detection of pre-clinical Alzheimer's disease across diverse participants.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Observational
- Plasma biomarkers, brain amyloid-beta pathology, and cortical thickness in a non-Hispanic White and Black/African American middle-aged community cohort: The HCP-CoBRA study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Plasma p-tau217 and incident mild cognitive impairment and dementia in older women: 25-year prospective study in The Women's Health Initiative Memory Study.medRxiv : the preprint server for health sciences · 2025Article
- Introduction to the special issue on ethics and equity in implementing novel biomarkers for Alzheimer's disease and related dementias: current progress and new directions.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Plasma p-tau217 and cognitive impairment: Evaluating biomarker equity across racial/ethnic groups in HABS-HD.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
introductionConsistent predictive performance across racial and ethnic groups is essential to the use of plasma biomarkers as screening tools in preclinical Alzheimer's disease trials.
methodsLogistic regression examined racial and ethnic group differences in plasma eligibility using an algorithm that included Phosphorylated tau217 to non-phosphorylated tau217 ratio, amyloid beta 42/40, age, and apolipoprotein E to predict > 18 Centiloids on amyloid imaging in cognitively unimpaired individuals.
resultsAmong 6437 participants screened, with non-Hispanic (NH) White as the reference group, odds ratios of plasma ineligibility were 2.88 (95% confidence interval [CI]: 1.40-6.96) for Hispanic Black, 1.60 (95% CI: 1.33-1.92) for Hispanic White, 2.10 (95% CI: 1.37-3.38) for NH Asian, and 1.59 (95% CI: 1.27-2.0) for NH Black participants. Positron emission tomography (PET) eligibility rates did not differ among those who were plasma eligible. DISCUSSION: Differential rates of plasma eligibility, but consistent PET eligibility among plasma-eligible participants, were observed, supporting the use of universal biomarker cutpoints across race and ethnic groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.